Many biotech firms would have nearly eight years to unwind contracts with questionable foreign firms under a new version of the BIOSECURE Act, a dramatic shift from earlier drafts that is a likely nod to industry’s requests and the reality of business.
The House bill would prevent US government agencies from obtaining equipment or services from a “biotechnology company of concern,”...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?